Dr Kraus is currently the Managing Partner at GDS Partners LLC, a firm specializing in Global Medicine R&D and business support from molecule identification through end Life Cycle. Dr Kraus is also a member of the Advisory Board at the NDA Group and a Yale University Entrepreneur in Residence. He has recently completed a 4-year term advising the US Food and Drug Administration as one of the two regulated industry representative members on the Oncologic Drugs Advisory Committee. Prior to that Albert served in several roles at Pfizer, including the IBRANCE Global Regulatory Franchise Leader, member of the Therapeutic Review Committee providing governance for all Oncology Therapeutics in Early Development, Chair of the Enterprise Wide Regulatory Portfolio Review Committee that provided C-suite leadership input and risk assessments for all Pfizer medicines for all Therapeutic areas, and member of the CT R&D leadership team (Pfizers largest R&D site worldwide). While at Pfizer Albert helped build the oncology therapeutic area from an acquired $1B business with few medicines to a $12+B business with over 25 medicines. Prior to joining Pfizer in early 2011, Albert was a Vice President and Executive Management Team member leading Regulatory Affairs, Pharmacovigilance, Quality Assurance, and/or Clinical Development at Onyx, Proteolix and Kosan Biosciences (San Francisco Bay area Biotech Companies). Prior to that Albert held positions of increasing responsibility at Bristol-Myers Squibb (including 4 years in a European role based in Belgium) culminating as a Group Director leading Worldwide Oncology Regulatory Affairs and FDA liaison activities. While at BMS, Albert was instrumental in the Medarex/ BMS collaboration that culminated in the advent of modern immuno-oncology medicines, including BMS’s ipilimumab and nivolumab (both Medarex acquisitions). Albert began his industry career at Procter & Gamble and while there held positions of increasing responsibility in the pharmacology, toxicology, clinical safety, and regulatory areas. Albert has worked primarily in Oncology, Metabolic, Immunology, Rare Disease, and Dermatology therapeutic areas and participated in the development of numerous small molecules and biologicals from research through end of life cycle stages. Albert received a BA from Hamilton College, with concentrations in Biology and Economics, and earned a PhD in biochemical toxicology/ cellular chemistry from the University of Michigan.